Breakaway From Cancer(R) Launches Newly-Enhanced Website

AmgenAs part of its ongoing mission to serve cancer patients, Amgen's Breakaway from Cancer(R) initiative announced the launch of its enhanced website that provides cancer patients, survivors, and caregivers a 'one-stop shop' of essential resources spanning cancer prevention, education, patient care, advocacy, and financial support.

The website, www.breakawayfromcancer.com, features a powerful new cancer resource navigator tool developed to help cancer patients maneuver through the complicated maze of online information that currently exists. The tool conducts a targeted search based on user-entered criteria from more than 100 hand-selected credible cancer websites to offer patients the information they need.

"Many valuable cancer resources exist, but it is sometimes hard for patients to identify what information applies to them," says Stuart Arbuckle, vice president and general manager, Amgen Oncology. "The enhanced Breakaway from Cancer website pulls information from credible sources and provides a support system and the necessary tools to help patients find exactly the resources they need in their fight against this devastating disease."

Breakaway from Cancer represents a partnership between Amgen and four nonprofit organizations to raise awareness of the broad range of support services available to patients and caregivers to complement those provided by healthcare professionals.

The newly-enhanced website also provides detailed information on the resources and assistance offered by the Breakaway from Cancer nonprofit partners: Prevent Cancer Foundation, Cancer Support Community (formerly known as The Wellness Community), Patient Advocate Foundation, and National Coalition for Cancer Survivorship. Patients are now also able to share and read inspirational stories from across the nation and keep up with the latest news and events from Breakaway from Cancer.

"Nearly everyone has been touched by cancer and felt the burden of this disease; however, far fewer individuals are aware of the full spectrum of help available," said Carolyn R. Aldige, president and founder, Prevent Cancer Foundation. "We are proud to team up with Breakaway from Cancer to offer consolidated resources like those on the new website to support patients."

About Breakaway from Cancer(R)
Founded in 2005 by Amgen as a complementary component to the company's title sponsorship of the Amgen Tour of California, Breakaway from Cancer is designed to help empower people affected by cancer. Breakaway from Cancer supports the services of four nonprofit organizations: Prevent Cancer Foundation, Cancer Support Community (formerly known as The Wellness Community), Patient Advocate Foundation, and National Coalition for Cancer Survivorship. For more information, please visit www.breakawayfromcancer.com.

About Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...